Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9936254 | 0.92 | LMNA (0.40) | LMNAGGPS1L3MBTL1PABPC1KMT2A | |
| SCHEMBL9934761 | 0.79 | BCHE (0.37) | PABPC1 | |
| SCHEMBL6114658 | 0.78 | PABPC1 (0.50) | LMNAGGPS1L3MBTL1PABPC1KMT2A | |
| SCHEMBL21523393 | 0.76 | PABPC1 (0.53) | LMNAGGPS1L3MBTL1PABPC1KDM4E | |
| SCHEMBL9935131 | 0.76 | C5AR1 (0.30) | — | |
| SCHEMBL9936116 | 0.75 | HTT (0.33) | L3MBTL1KMT2AKDM4EALDH1A1 | |
| SCHEMBL21523397 | 0.75 | PABPC1 (0.48) | LMNAGGPS1L3MBTL1PABPC1KMT2A | |
| SCHEMBL9934636 | 0.75 | ACHE (0.34) | L3MBTL1KMT2AKDM4EALDH1A1 | |
| SCHEMBL29252632 | 0.74 | LMNA (0.43) | LMNAGGPS1L3MBTL1PABPC1KMT2A | |
| SCHEMBL1461724 | 0.74 | LMNA (0.45) | LMNAGGPS1L3MBTL1PABPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546609-B2 | Ionic liquid containing allylsulfonate anion | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2013-10-01 | — | — | US | disclosed |
| EP-2474527-A1 | IONIC LIQUID CONTAINING ALLYLSULFONATE ANION | Wako Pure Chemical Industries, Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20120157680-A1 | IONIC LIQUID CONTAINING ALLYLSULFONATE ANION | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157680-A1 | IONIC LIQUID CONTAINING ALLYLSULFONATE ANION | ATXN2L, ARL1, INPPL1 | LMNA 3421/4885GGPS1 2730/4885L3MBTL1 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.